Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
Add more filters










Publication year range
1.
J Nat Prod ; 87(4): 722-732, 2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38408345

ABSTRACT

The first detailed phytochemical analysis of the cannabigerol (CBG)-rich chemotype IV of Cannabis sativa L. resulted in the isolation of the expected cannabigerolic acid/cannabigerol (CBGA/CBG) and cannabidiolic acid/cannabidiol (CBDA/CBD) and of nine new phytocannabinoids (5-13), which were fully characterized by HR-ESIMS and 1D and 2D NMR. These included mono- or dihydroxylated CBGA/CBG analogues, a congener with a truncated side chain (10), cyclocannabigerol B (11), and the CBD derivatives named cannabifuranols (12 and 13). Cyclocannabigerol B and cannabifuranols are characterized by a novel phytocannabinoid structural architecture. The isolated phytocannabinoids were assayed on the receptor channels TRPA1 and TRPM8, unveiling a potent dual TRPA1 agonist/TRPM8 antagonist profile for compounds 6, 7, and 14. Chiral separation of the two enantiomers of 5 resulted in the discovery of a synergistic effect of the two enantiomers on TRPA1.


Subject(s)
Cannabinoids , Cannabis , TRPA1 Cation Channel , TRPM Cation Channels , Transient Receptor Potential Channels , Cannabis/chemistry , TRPA1 Cation Channel/antagonists & inhibitors , Cannabinoids/pharmacology , Cannabinoids/chemistry , Cannabinoids/isolation & purification , TRPM Cation Channels/antagonists & inhibitors , Molecular Structure , Transient Receptor Potential Channels/antagonists & inhibitors , Transient Receptor Potential Channels/drug effects , Phytochemicals/pharmacology , Phytochemicals/isolation & purification , Phytochemicals/chemistry , Humans , Cannabidiol/pharmacology , Cannabidiol/chemistry , Calcium Channels/metabolism
2.
J Med Chem ; 66(10): 6994-7015, 2023 05 25.
Article in English | MEDLINE | ID: mdl-37192374

ABSTRACT

We describe an in silico-guided rational drug design and the synthesis of the suggested ligands, aimed at improving the TRPV1-ligand binding properties and the potency of N-(4-hydroxy-3-methoxybenzyl)-4-(thiophen-2-yl) butanamide I, a previously identified TRPV1 agonist. The docking experiments followed by molecular dynamics simulations and thermodynamic analysis led the drug design toward both the introduction of a lipophilic iodine and a flat pyridine/benzene at position 5 of the thiophene nucleus. Most of the synthesized compounds showed high TRPV1 efficacy and potency as well as selectivity. The molecular modeling analysis highlighted crucial hydrophobic interactions between Leu547 and the iodo-thiophene nucleus, as in amide 2a, or between Phe543 and the pyridinyl moiety, as in 3a. In the biological evaluation, both compounds showed protective properties against oxidative stress-induced ROS formation in human keratinocytes. Additionally, while 2a showed neuroprotective effects in both neurons and rat brain slices, 3a exhibited potent antinociceptive effect in vivo..


Subject(s)
Molecular Dynamics Simulation , Thiophenes , Rats , Animals , Humans , Thiophenes/pharmacology , Thiophenes/chemistry , Oxidative Stress , Amides , Drug Design , Molecular Docking Simulation , TRPV Cation Channels/agonists
3.
Methods Mol Biol ; 2576: 119-131, 2023.
Article in English | MEDLINE | ID: mdl-36152181

ABSTRACT

The transient receptor potential vanilloid 1 ion channel (TRPV1) is a ligand-gated nonselective calcium-permeant cation channel involved in the detection of a wide variety of chemical and physical noxious stimuli, ranging from exogenous and endogenous ligands to noxious heat (>42 °C) and low pH (pH < 5.2). Due to its central role in pain and hyperalgesia, TRPV1 is considered a relevant therapeutic target for the development of analgesic and anti-inflammatory drugs potentially useful to relieve chronic, neuropathic, and inflammatory pain and to treat disorders such as inflammatory bowel disease. In this view, the availability of in vitro assays for the screening of novel TRPV1 modulators is highly desirable. Since TRPV1 activation leads to an increase in the intracellular calcium (Ca2+) levels, the use of Ca2+ fluorescent indicators represent a valuable and sensitive tool for monitoring such intracellular changes. In this chapter, we describe methods for recording and monitoring Ca2+ signals through the fluorescent indicators Fluo-4 acetoxymethyl (AM) and Fura-2 AM in HEK-293 cells transfected with TRPV1 or other thermoTRP channels.


Subject(s)
Transient Receptor Potential Channels , Analgesics , Calcium/metabolism , Capsaicin , Cations , Fluorescence , Fura-2 , HEK293 Cells , Humans , Ligands , Pain/drug therapy , TRPV Cation Channels/physiology
4.
J Nat Prod ; 83(11): 3476-3481, 2020 11 25.
Article in English | MEDLINE | ID: mdl-33136399

ABSTRACT

As part of a study on triterpenoid conjugates, the dietary pentacyclic triterpenoids oleanolic (2a) and ursolic acids (3a) were coupled with vanillamine, and the resulting amides (2b and 3b, respectively) were assayed for activity on the vanilloid receptor TRPV1. Despite a structural difference limited to the location of a methyl group in their conformationally rigid pentacyclic core, oleanoloyl vanillamide dramatically outperformed ursoloyl vanillamide in terms of potency (EC50 = 35 ± 2 nM for 2b and 5.4 ± 2.3 µM for 3b). Using molecular docking and dynamics, this difference was translated into distinct accommodation modes at the TRPV1 vanillyl ligand pocket, suggesting a critical role of a C-H πphenyl interaction between the triterpenoid C-29 methyl and Phe591 of TRPV1. Because the molecular mechanisms underlying the activation process of transient receptor channels (TRPs) remain to be fully elucidated, the observation of spatially restricted structure-activity information is of significant relevance to identify the molecular detail of TRPV1 ligand gating.


Subject(s)
Amides/chemistry , Drug Discovery , TRPV Cation Channels/drug effects , Triterpenes/pharmacology , HEK293 Cells , Humans , Molecular Docking Simulation , Triterpenes/chemistry
5.
Int J Biol Macromol ; 138: 658-666, 2019 Oct 01.
Article in English | MEDLINE | ID: mdl-31344416

ABSTRACT

Ten Halomonas strains were screened from different Tunisian hypersaline environments for the production of exopolysaccharides (EPS), characterized and identified basing on 16S rRNA gene sequencing. EPS production was therefore studied using two different culture media M1 (complex medium) and M2 (semi-complex medium). Selected isolates produced different EPS amounts ranging from 86 to 170 mg L-1 and 26 to 105 mg L-1 when grown on M1 and M2, respectively. The use of M1 encouraged stronger bacterial growth associated with greater EPS production compared to M2. Nevertheless, the highest EPS yield (YEPS/X) was observed for strains grown on M2. When cultivated on M1, all isolates produced EPS exhibiting almost the same monosaccharide profile with mannose, glucose and arabinose being the main monomers. However, the produced EPS on M2 were characterized by heterogeneous monosaccharide profiles among the different species, mostly consisting of glucomannan that could be a versatile material used for many further applications.


Subject(s)
Environment , Halomonas/physiology , Polysaccharides, Bacterial/biosynthesis , Saline Solution, Hypertonic , Chemical Phenomena , Culture Media , Geography , Halomonas/classification , Monosaccharides , Phylogeny , Tunisia
6.
Br J Pharmacol ; 176(10): 1568-1584, 2019 05.
Article in English | MEDLINE | ID: mdl-30074247

ABSTRACT

BACKGROUND AND PURPOSE: Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, results in chronic inflammation and irreversible skeletal muscle degeneration. Moreover, the associated impairment of autophagy greatly contributes to the aggravation of muscle damage. We explored the possibility of using non-euphoric compounds present in Cannabis sativa, cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabidivarin (THCV), to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo. EXPERIMENTAL APPROACH: Using quantitative PCR, western blots and [Ca2+ ]i measurements, we explored the effects of CBD and CBDV on the differentiation of both murine and human skeletal muscle cells as well as their potential interaction with TRP channels. Male dystrophic mdx mice were injected i.p. with CBD or CBDV at different stages of the disease. After treatment, locomotor tests and biochemical analyses were used to evaluate their effects on inflammation and autophagy. KEY RESULTS: CBD and CBDV promoted the differentiation of murine C2C12 myoblast cells into myotubes by increasing [Ca2+ ]i mostly via TRPV1 activation, an effect that undergoes rapid desensitization. In primary satellite cells and myoblasts isolated from healthy and/or DMD donors, not only CBD and CBDV but also THCV promoted myotube formation, in this case, mostly via TRPA1 activation. In mdx mice, CBD (60 mg·kg-1 ) and CBDV (60 mg·kg-1 ) prevented the loss of locomotor activity, reduced inflammation and restored autophagy. CONCLUSION AND IMPLICATIONS: We provide new insights into plant cannabinoid interactions with TRP channels in skeletal muscle, highlighting a potential opportunity for novel co-adjuvant therapies to prevent muscle degeneration in DMD patients. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.


Subject(s)
Cannabidiol/pharmacology , Cannabinoids/pharmacology , Cannabis/chemistry , Dronabinol/analogs & derivatives , Muscle, Skeletal/drug effects , Muscular Dystrophy, Duchenne/drug therapy , Myoblasts/drug effects , Animals , Calcium/metabolism , Cannabidiol/isolation & purification , Cannabinoids/isolation & purification , Cell Differentiation/drug effects , Cell Line , Dose-Response Relationship, Drug , Dronabinol/isolation & purification , Dronabinol/pharmacology , Dystrophin/genetics , Endocannabinoids/metabolism , Humans , Male , Mice , Muscle Strength/drug effects , Muscle Strength/genetics , Muscle, Skeletal/metabolism , Muscular Dystrophy, Duchenne/metabolism , Myoblasts/metabolism , Transient Receptor Potential Channels/metabolism
7.
J Nat Prod ; 81(3): 630-633, 2018 03 23.
Article in English | MEDLINE | ID: mdl-29240420

ABSTRACT

Treatment with iodine cleanly converts various p-menthane-type phytocannabinoids and their carboxylated precursors into cannabinol (CBN, 1a). The reaction is superior to previously reported protocols in terms of simplicity and substrate range, which includes not only tricyclic tetrahydrocannabinols such as Δ9-THC (2a) but also bicyclic phytocannabinoids such as cannabidiol (CBD, 3a). Lower homologues from the viridin series (2c and 3c, respectively) afforded cannabivarin (CBV), a non-narcotic compound that, when investigated against a series of ionotropic (thermo-TRPs) biological end-points of phytocannabinoids, retained the submicromolar TRPA1-activating and TRPM8-inhibiting properties of CBN, while also potently activating TRPV2. Treatment with iodine provides an easy access to CBN (1a) from crude extracts and side-cuts of the purification of Δ9-THC and CBD from respectively narcotic Cannabis sativa (marijuana) and fiber hemp, substantially expanding the availability of this compound and, in the case of fiber hemp, dissecting it from narcotic phytocannabinoids.


Subject(s)
Cannabinoid Receptor Agonists/chemistry , Iodine/chemistry , Cannabidiol/chemistry , Cannabidiol/pharmacology , Cannabinoid Receptor Agonists/pharmacology , Cannabinoids/chemistry , Cannabinoids/pharmacology , Cannabinol/chemistry , Cannabinol/pharmacology , Cannabis/chemistry , Cell Line , Dronabinol/chemistry , Dronabinol/pharmacology , HEK293 Cells , Humans , TRPA1 Cation Channel/metabolism , TRPV Cation Channels/metabolism
8.
Methods Mol Biol ; 1412: 65-76, 2016.
Article in English | MEDLINE | ID: mdl-27245892

ABSTRACT

The transient receptor potential vanilloid-1 ion channel (TRPV1) is a non-selective ligand-gated cation channel. It is an integrator of a wide variety of exogenous and endogenous physical and chemical stimuli, including capsaicin, noxious heat (>42 °C), and protons (pH < 5.2). TRPV1 is expressed predominantly in primary sensory neurons involved in pain sensation, but also in other neuronal cell types, in the plasma membrane of different non-neuronal cells such as immune cells, keratinocytes, smooth muscle cells, and in the urothelium. Some of these cell types are involved in inflammation. When activated, TRPV1 leads to the gating of cations, including Ca(2+), thus generating changes in intracellular Ca(2+) concentration. Calcium ions play fundamental roles in many cellular processes, virtually in all cells. The use of Ca(2+) fluorescent indicators is a tool for monitoring intracellular Ca(2+) concentration.In this chapter, we describe a method for recording and monitoring Ca(2+) signals through the single wavelength fluorescent indicator Fluo-4 acetoxymethyl (AM), and the ratiometric fluorescent indicator Fura-2 AM in HEK-293 cells transfected with TRPV1 and other TRP channels. TRPV1 pharmacological modulation may potentially represent a strategy for the control of pain and inflammatory conditions in a variety of diseases and injury states.


Subject(s)
Signal Transduction , Spectrometry, Fluorescence , TRPV Cation Channels/metabolism , Aniline Compounds , Calcium/metabolism , Fluorescent Dyes , Fura-2 , Gene Expression , HEK293 Cells , Humans , Spectrometry, Fluorescence/methods , TRPV Cation Channels/genetics , Xanthenes
9.
CNS Neurol Disord Drug Targets ; 15(8): 987-994, 2016.
Article in English | MEDLINE | ID: mdl-27071783

ABSTRACT

Eleven compounds belonging to the chalcone family were tested for their ability to activate and subsequently desensitize the rat transient receptor potential ankyrin 1 cation channel, subfamily A, member 1 (TRPA1) in a heterologous expression system. Four of the tested compounds were more potent than the TRPA1 agonist mustard oil, and showed also a strong desensitizing effect. Some chalcone compounds were not pungent in the eye-wiping assay and quite remarkably inhibited in a long-lasting and dose-dependent manner the pain response in the formalin test. Chalcones can be considered as novel candidates for the development of antihyperalgesic preparations based on TRPA1 desensitization.


Subject(s)
Analgesics/chemistry , Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Chalcones/therapeutic use , Inflammation/drug therapy , Pain/drug therapy , Transient Receptor Potential Channels/metabolism , Animals , Anti-Inflammatory Agents/chemistry , Calcium/metabolism , Chalcones/chemistry , Disease Models, Animal , Dose-Response Relationship, Drug , Formaldehyde/toxicity , HEK293 Cells , Humans , Inflammation/chemically induced , Male , Mice , Mice, Inbred C57BL , Mustard Plant/toxicity , Pain/chemically induced , Pain Measurement , Plant Oils/toxicity , Rats , Structure-Activity Relationship , TRPA1 Cation Channel , Transient Receptor Potential Channels/chemistry
10.
Bioorg Med Chem Lett ; 26(3): 899-902, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26750258

ABSTRACT

A series of twenty resveratrol analogues was synthesized and tested on TRPA1 and TRPV1 channels. None was able to significantly modulate TRPV1 channels. Conversely, most of them exhibited remarkably higher TRPA1 modulating activity than resveratrol. Optimal potency was observed with ortho monoxygenated stilbenes 6 and 17.


Subject(s)
Stilbenes/chemistry , TRPC Cation Channels/metabolism , Animals , Calcium/metabolism , HEK293 Cells , Humans , Inhibitory Concentration 50 , Ion Transport/drug effects , Protein Binding , Rats , Resveratrol , Stilbenes/metabolism , Stilbenes/pharmacology , TRPA1 Cation Channel , TRPC Cation Channels/chemistry , TRPC Cation Channels/genetics
12.
Mar Drugs ; 10(11): 2435-47, 2012 Nov 02.
Article in English | MEDLINE | ID: mdl-23203269

ABSTRACT

Leucettamols, bifunctionalized sphingoid-like compounds obtained from a marine sponge Leucetta sp., act as non-electrophilic activators of the TRPA1 channel and potent inhibitors of the icilin-mediated activation of the TRPM8 channel, while they are inactive on CB1, CB2 and TRPV1 receptors. Leucettamols represent the first compounds of marine origin to target TRPA1 and the first class of natural products to inhibit TRPM8 channels. The preparation of a small series of semi-synthetic derivatives revealed interesting details on the structure-activity relationships within this new chemotype of simple acyclic TRP modulators.


Subject(s)
Porifera/chemistry , Sphingolipids/pharmacology , TRPC Cation Channels/drug effects , TRPM Cation Channels/antagonists & inhibitors , Animals , HEK293 Cells , Humans , Rats , Receptor, Cannabinoid, CB1/drug effects , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/drug effects , Receptor, Cannabinoid, CB2/metabolism , Sphingolipids/chemistry , Sphingolipids/isolation & purification , Structure-Activity Relationship , TRPA1 Cation Channel , TRPC Cation Channels/metabolism , TRPM Cation Channels/metabolism , TRPV Cation Channels/drug effects , TRPV Cation Channels/metabolism
13.
Bioorg Med Chem Lett ; 22(10): 3535-9, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22503249

ABSTRACT

A series of thirty-three thymol, p-cymene-3-carboxylic acid, and 3-amino-p-cymene derivatives was synthesized and tested on TRPA1, TRPM8, and TRPV3 channels. Most of them acted as strong modulators of TRPA1, TRPM8, and TRPV3 channels with EC(50) and/or IC(50) values distinctly lower than those of thymol and related monoterpenoids. Some of the compounds examined, that is, 3c, 4e, f, 6b, and 8b exhibited an appreciable subtype-selectivity.


Subject(s)
Thymol/pharmacology , Transient Receptor Potential Channels/drug effects , Animals , Cell Line , Humans , Rats , Thymol/chemistry
14.
Bioorg Med Chem Lett ; 22(4): 1674-7, 2012 Feb 15.
Article in English | MEDLINE | ID: mdl-22257892

ABSTRACT

In order to explore the structural determinants for the TRPV1 and TRPA1 agonist properties of gingerols, a series of nineteen analogues (1b-5) of racemic [6]-gingerol (1a) was synthesized and tested on TRPV1 and TRPA1 channels. The exploration of the structure-activity relationships, by modulating the three pharmacophoric regions of [6]-gingerol, led to the identification of some selective TRPV1 agonists/desensitizers of TRPV1 channels (3a, 3f, and 4) and of some full TRPA1 antagonists (2c, 2d, 3b, and 3d).


Subject(s)
Catechols/chemical synthesis , Fatty Alcohols/chemical synthesis , Nerve Tissue Proteins/agonists , TRPV Cation Channels/agonists , Transient Receptor Potential Channels/agonists , Calcium Channels , Catechols/chemistry , Catechols/pharmacology , Fatty Alcohols/chemistry , Fatty Alcohols/pharmacology , Humans , Inhibitory Concentration 50 , Molecular Structure , Nerve Tissue Proteins/antagonists & inhibitors , Protein Binding/drug effects , Stereoisomerism , Structure-Activity Relationship , TRPA1 Cation Channel , TRPV Cation Channels/antagonists & inhibitors , Transient Receptor Potential Channels/antagonists & inhibitors
15.
Pharmacol Res ; 63(4): 294-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21215315

ABSTRACT

N-acyl-vanillamide (NAVAM) analogues of the natural pungent principle of capsicum, capsaicin, were developed several years ago as potential non-pungent analgesic compounds. N-oleoyl-vanillamide (olvanil) and N-arachidonoy-vanillamide (arvanil), in particular, were described in several publications and patents to behave as potent anti-hyperalgesic compounds in experimental models of chronic and inflammatory pain, and to activate both "capsaicin receptors", i.e. the transient receptor potential of vanilloid type-1 (TRPV1) channel, and, either directly or indirectly, cannabinoid receptors of type-1. Here we report the biochemical and pharmacological characterization of a so far neglected NAVAM, N-palmitoyl-vanillamide (palvanil), and propose its possible use instead of capsaicin, as a possible topical analgesic. Palvanil exhibited a kinetics of activation of human recombinant TRPV1-mediated intracellular calcium elevation significantly slower than that of capsaicin (t(1/2)=21s and 8s, respectively at 1µM). Slow kinetics of TRPV1 agonists were previously found to be associated with stronger potencies as TRPV1 desensitizing agents, which in turn are usually associated with lower pungency and stronger anti-hyperalgesic activity. Accordingly, palvanil desensitized the human recombinant TRPV1 to the effect of capsaicin (10nM) with significantly higher potency than capsaicin (IC(50)=0.8nM and 3.8nM, respectively), this effect reaching its maximum more rapidly (50 and 250min, respectively). Palvanil was also more potent than capsaicin at desensitizing the stimulatory effect of TRPV1 by low pH together with anandamide, which mimics conditions occurring during inflammation. In the eye-wiping assay carried out in mice, palvanil was not pungent and instead caused a strong and long-lasting inhibition of capsaicin-induced eye-wiping. Finally, intraplantar palvanil inhibited the second phase of the nociceptive response to formalin in mice. In conclusion, palvanil appears to be a non-pungent analogue of capsaicin with stronger desensitizing effects on TRPV1 and hence potentially higher anti-hyperalgesic activity.


Subject(s)
Analgesics/therapeutic use , Capsaicin/analogs & derivatives , Pain/drug therapy , TRPV Cation Channels/metabolism , Administration, Topical , Analgesics/pharmacology , Animals , Arachidonic Acids/pharmacology , Calcium/metabolism , Capsaicin/pharmacology , Capsaicin/therapeutic use , Cell Line , Endocannabinoids , Eye/drug effects , Humans , Male , Mice , Polyunsaturated Alkamides/pharmacology
16.
Br J Pharmacol ; 163(7): 1479-94, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21175579

ABSTRACT

BACKGROUND AND PURPOSE: Cannabidiol (CBD) and Δ(9) -tetrahydrocannabinol (THC) interact with transient receptor potential (TRP) channels and enzymes of the endocannabinoid system. EXPERIMENTAL APPROACH: The effects of 11 pure cannabinoids and botanical extracts [botanical drug substance (BDS)] from Cannabis varieties selected to contain a more abundant cannabinoid, on TRPV1, TRPV2, TRPM8, TRPA1, human recombinant diacylglycerol lipase α (DAGLα), rat brain fatty acid amide hydrolase (FAAH), COS cell monoacylglycerol lipase (MAGL), human recombinant N-acylethanolamine acid amide hydrolase (NAAA) and anandamide cellular uptake (ACU) by RBL-2H3 cells, were studied using fluorescence-based calcium assays in transfected cells and radiolabelled substrate-based enzymatic assays. Cannabinol (CBN), cannabichromene (CBC), the acids (CBDA, CBGA, THCA) and propyl homologues (CBDV, CBGV, THCV) of CBD, cannabigerol (CBG) and THC, and tetrahydrocannabivarin acid (THCVA) were also tested. KEY RESULTS: CBD, CBG, CBGV and THCV stimulated and desensitized human TRPV1. CBC, CBD and CBN were potent rat TRPA1 agonists and desensitizers, but THCV-BDS was the most potent compound at this target. CBG-BDS and THCV-BDS were the most potent rat TRPM8 antagonists. All non-acid cannabinoids, except CBC and CBN, potently activated and desensitized rat TRPV2. CBDV and all the acids inhibited DAGLα. Some BDS, but not the pure compounds, inhibited MAGL. CBD was the only compound to inhibit FAAH, whereas the BDS of CBC > CBG > CBGV inhibited NAAA. CBC = CBG > CBD inhibited ACU, as did the BDS of THCVA, CBGV, CBDA and THCA, but the latter extracts were more potent inhibitors. CONCLUSIONS AND IMPLICATIONS: These results are relevant to the analgesic, anti-inflammatory and anti-cancer effects of cannabinoids and Cannabis extracts.


Subject(s)
Cannabinoid Receptor Modulators/metabolism , Cannabinoids/pharmacology , Cannabis/chemistry , Endocannabinoids , Transient Receptor Potential Channels/agonists , Transient Receptor Potential Channels/antagonists & inhibitors , Amides , Amidohydrolases/metabolism , Animals , Arachidonic Acids/metabolism , COS Cells , Chlorocebus aethiops , Ethanolamines , Glycerides/metabolism , HEK293 Cells , Humans , Lipoprotein Lipase/metabolism , Monoacylglycerol Lipases/metabolism , Palmitic Acids/metabolism , Plant Extracts/pharmacology , Polyunsaturated Alkamides/metabolism , Rats , Transient Receptor Potential Channels/metabolism
17.
PLoS One ; 5(4): e10239, 2010 Apr 22.
Article in English | MEDLINE | ID: mdl-20422025

ABSTRACT

BACKGROUND: Considerable efforts have been made to characterize the pathways regulating the extracellular levels of the endocannabinoid anandamide. However, none of such pathways has been so argued as the existence of a carrier-mediated transport of anandamide across the membrane. Apart from the lack of molecular evidence for such a carrier, the main reasons of this controversy lie in the methodologies currently used to study anandamide cellular uptake. Furthermore, the main evidence in favor of the existence of an "anandamide transporter" relies on synthetic inhibitors of this process, the selectivity of which has been questioned. METHODOLOGY/PRINCIPAL FINDINGS: We used the cytosolic binding site for anandamide on TRPV1 channels as a biosensor to detect anandamide entry into cells, and exploited nanotechnologies to study anandamide membrane transport into intact TRPV1-overexpressing HEK-293 cells. Both fluorescence and digital holographic (DH) quantitative phase microscopy were used to study TRPV1 activation. Poly-epsilon-caprolactone nanoparticles (PCL-NPs) were used to incorporate anandamide, which could thus enter the cell and activate TRPV1 channels bypassing any possible specific protein(s) involved in the uptake process. We reasoned that in the absence of such protein(s), pharmacological tools previously shown to inhibit the "anandamide transporter" would affect in the same way the uptake of anandamide and PCL-NP-anandamide, and hence the activation of TRPV1. However, when masked into PCL-NPs, anandamide cellular uptake became much less sensitive to these agents, although it maintained the same pharmacokinetics and pharmacodynamics as that of "free" anandamide. CONCLUSIONS: We found here that several agents previously reported to inhibit anandamide cellular uptake lose their efficacy when anandamide is prevented from interacting directly with plasma membrane proteins, thus arguing in favor of the specificity of such agents for the putative "anandamide transporter", and of the existence of such mechanism.


Subject(s)
Arachidonic Acids/metabolism , Drug Carriers/pharmacology , Membrane Transport Proteins/metabolism , Polyunsaturated Alkamides/metabolism , TRPV Cation Channels/metabolism , Arachidonic Acids/administration & dosage , Binding Sites , Calcium Channel Blockers , Cannabinoid Receptor Modulators , Cell Line , Drug Carriers/chemistry , Endocannabinoids , Humans , Polyesters , Polyunsaturated Alkamides/administration & dosage , TRPV Cation Channels/pharmacokinetics
18.
Bioorg Med Chem Lett ; 20(9): 2729-32, 2010 May 01.
Article in English | MEDLINE | ID: mdl-20378345

ABSTRACT

A series of twenty-two (-)-menthylamine derivatives was synthesized and tested on TRPM8, TRPV1, and TRPA1 channels. Five of the novel compounds, that is, 1d, 1f, 2b, 2c, and 2e behaved as potent TRPM8 antagonists with IC(50) values versus icilin and (-)-menthol between 20 nM and 0.7 microM, and were between 4- and approximately 150-fold selective versus TRPV1 and TRPA1 activation. Compound 1d also induced caspase 3/7 release in TRPM8-expressing LNCaP prostate carcinoma cells, but not in non-TRPM8 expressing DU-145 cells. Five other derivatives, that is, 1a, 1g, 1h, 2f, and 2h were slightly less potent than previous compounds but still relatively selective versus TRPV1 and TRPA1.


Subject(s)
Antineoplastic Agents/chemistry , Menthol/analogs & derivatives , TRPM Cation Channels/antagonists & inhibitors , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Caspase 3/metabolism , Caspase 7/metabolism , Cell Line, Tumor , Humans , Menthol/chemical synthesis , Menthol/pharmacology , Stereoisomerism , Structure-Activity Relationship , TRPM Cation Channels/metabolism
20.
Biochim Biophys Acta ; 1793(7): 1289-303, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19445974

ABSTRACT

Although coupled to G(i/o) proteins, cannabinoid CB(1) receptors can also activate intracellular Ca(2+) ([Ca(2+)](i)) accumulation through not fully understood mechanisms. We report that in, human neuroblastoma SH-SY5Y cells, CB(1) activation with the specific agonist arachidonoylchloroethanolamide (ACEA), weakly elevates [Ca(2+)](i) and that this effect, when using low (1-100 nM) concentrations of ACEA, is enhanced by the previous activation of G(q/11)-coupled M(3) muscarinic receptors with carbachol, dose-dependently and up to approximately 8-fold. A similar behaviour was also observed with carbachol and the G(i/o)-coupled delta-opioid receptor. Furthermore, stimulation of CB(1) receptors produced a concentration-dependent leftward shift of the elevation of [Ca(2+)](i) by delta-opioid receptors. These stimulatory effects were variedly attenuated by selective antagonists of each receptor, pertussis toxin, inhibitors of phospholipase C (U73122 and D609), and, when assessed in the presence of extracellular Ca(2+), by the block of voltage-activated calcium channels. Cholera toxin only slightly inhibited the G(q/11)-G(i/o)-mediated cross-talk, but induced a stronger inhibition of the G(i/o)-G(i/o)-mediated interaction. These findings suggest that activation of M(3) muscarinic receptors might produce a qualitative alteration of the signaling associated with G(i/o)-coupled receptors, and that sequential activation of CB(1) and delta-opioid receptors, both coupled to G(i/o), produces instead synergistic effects on [Ca(2+)](i) elevation.


Subject(s)
Calcium/metabolism , Neuroblastoma/metabolism , Receptor, Cannabinoid, CB1/metabolism , Receptors, Muscarinic/metabolism , Receptors, Opioid, delta/metabolism , Blotting, Western , Fluorescent Antibody Technique , GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , GTP-Binding Protein alpha Subunits, Gq-G11/metabolism , Humans , Neuroblastoma/pathology , Receptor, Muscarinic M3/metabolism , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...